BioSpecifics Technologies Corporation Reports Second Quarter 2017 Financial Results
LYNBROOK, N.Y., Aug. 9, 2017 /PRNewswire/ -- BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2017 and provided a corporate update.